High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4 by Mariño, Zoe et al.
iver International. 2017; 37(12): 1823-1832 
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of 
Spanish cirrhotic patients infected with genotypes 1 and 4 
Zoe Mariño
1
, Juan M. Pascasio-Acevedo
2
, Adolfo Gallego
3
, Moisés Diago
4
, Carme Baliellas
5
, 
Rosa Morillas
6
, Martín Prieto
7
, José M. Moreno
8
, Gloria Sánchez-Antolín
9
, Mercedes Vergara
10
, 
Montserrat Forné
1
1, Inmaculada Fernández
12
, María A. Castro
13
, Sonia Pascual
14
, Alexandra 
Gómez
15
, Lluis Castells
16
, José L. Montero
17
, Javier Crespo
18
, José L. Calleja
19
, Javier García-
Samaniego
20
, Jose A. Carrión
21
, Ana C. Arencibia
22
, Alejandro Blasco
23
, Carmen López-
Núñez
24
, Juan J. Sánchez-Ruano
25
, Francisco Gea-Rodríguez
26
, Álvaro Giráldez
2
, Joaquín 
Cabezas
18
, Vanessa Hontangas
7
, Xavier Torras
3
, Jose Castellote
5
, Manuel Romero-Gómez
27
, 
Juan Turnes
28
, Tomás de Artaza
25
, Isidoro Narváez
29
, Valentín Cuervas-Mons
19
, Xavier Forns
1
 
1 Liver Unit, Hospital Clinic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i Sunyer 
(IDIBAPS) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 
Barcelona, Spain 
2 Clinical Management Unit of Digestive Diseases, Hospital Universitario Virgen del Rocío, CIBERehd, Sevilla, 
Spain 
3 Liver Unit, Hospital Santa Creu i Sant Pau, CIBERehd, Barcelona, Spain 
4 Digestive Diseases, Hospital Universitario General, Valencia, Spain 
5 Liver Unit, Hospital Universitari Bellvitge-Instituto de Investigación Biomédica de Bellvitge (IDIBELL), 
L’Hospitalet de Llobregat, Barcelona, Spain 
6 Liver Unit, Hospital Germans Trias i Pujol, CIBERehd, Badalona, Spain 
7 Liver Unit, Hospital Universitario La Fe, Valencia, Spain 
8 Department of Gastroenterology, Complejo Hospitalario Universitario de Albacete, Albacete, Spain 
9 Department of Gastroenterology, Hospital Universitario Río Hortega, Valladolid, Spain 
10 Liver Unit, Servei d’Aparell Digestiu, Parc Tauli Sabadell Hospital Universitari, Universitat Autónoma Barcelona, 
Sabadell, Spain 
11 Liver Unit, Hospital Universitario Mutua de Terrassa, Terrassa, Spain 
12 Liver Unit, Hospital Universitario 12 de Octubre, Madrid, Spain 
13 Internal Medicine, Grupo de Virología Clínica, Instituto Investigación Biomédica A Coruña (INIBIC)-Hospital 
Universitario A Coruña, A Coruña, Spain 
14 Liver Unit, Hospital General Universitario Alicante, CIBERehd, Alicante, Spain 
15 Liver Unit, Hospital Universitario Donostia, San Sebastian, Spain 
16 Liver Unit, Internal Medicine Department, Hospital Universitari Vall Hebron, CIBERehd, Barcelona, Spain 
17 Liver Unit, Hospital Universitario Reina Sofía, CIBERehd, Córdoba, Spain 
18 Gastroenterology and Hepatology Department, University Hospital Marqués de Valdecilla, IDIVAL, University of 
Cantabria, Santander, Spain 
19 Liver Unit, Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, CIBERehd, Madrid, Spain 
20 Liver Unit, Hospital Universitario La Paz, CIBERehd, IdiPAZ, Madrid, Spain 
21 Liver Section, Gastroenterology Department, Hospital del Mar, Universitat Autònoma de Barcelona, IMIM 
(Hospital del Mar Medical Research Institute), Barcelona, Spain 
22 Liver Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, Spain 
23 Digestive Diseases, Hospital de Sant Joan Despi Moises Broggi, Barcelona, Spain 
24 Digestive Diseases, Hospital Universitari Dr.Josep Trueta, Girona, Spain 
25 Digestive Diseases, Hospital Universitario de Toledo, Toledo, Spain 
26 Liver Unit, Hospital Ramón y Cajal, Madrid, Spain 
27 Liver Unit, Hospital Virgen de Valme, Sevilla, Spain 
28 Digestive Diseases, Complejo Hospitalario Universitario de Pontevedra and IISGS, Pontevedra, Spain 
29 Liver Unit, Hospital Infanta Cristina, Badajoz, Spain  
Abstract 
Background and Aims. Hepatitis C (HCV) therapy with Sofosbuvir (SOF)/Simeprevir (SMV) in clinical trials and 
real‐world clinical practice, showed high rates of sustained virological response (SVR) in non‐cirrhotic genotype 
(GT)‐1 and GT‐4 patients. These results were slightly lower in cirrhotic patients. We investigated real‐life 
effectiveness and safety of SOF/SMV with or without ribavirin (RBV) in a large cohort of cirrhotic patients. 
Methods. This collaborative multicentre study included data from 968 patients with cirrhosis infected with HCV‐GT1 
or 4, treated with SOF/SMV±RBV in 30 centres across Spain between January‐2014 and December‐2015. 
Demographic, clinical, virological and safety data were analysed. 
Results. Overall SVR was 92.3%; the majority of patients were treated with RBV (62%) for 12 weeks (92.4%). No 
significant differences in SVR were observed between genotypes (GT1a:94.3%; GT1b:91.7%; GT4:91.1%). Those 
patients with more advanced liver disease (Child B/C, MELD≥10) or portal hypertension (platelet count≤100×109/L, 
transient elastography≥21 Kpa) showed significantly lower SVR rates (84.4%‐91.9%) than patients with less 
advanced liver disease (93.8%‐95.9%, P<.01 in all cases). In the multivariate analysis, the use of RBV, female 
gender, baseline albumin≥35 g/L, MELD<10 and lack of exposure to a triple therapy regimen were independent 
predictors of SVR (P<.05). Serious adverse events (SAEs) and SAE‐associated discontinuation events occurred in 
5.9% and 2.6%.  
Conclusions. In this large cohort of cirrhotic patients managed in the real‐world setting in Spain, SOF/SMV±RBV 
yielded to excellent SVR rates, especially in patients with compensated liver cirrhosis. In addition, this combination 
showed to be safe, with low rates of SAEs and early discontinuations. 
Keywords 
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Abbreviations 
AE, adverse event; DAA, direct acting antivirals; GT, genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C 
virus; HR, hazard ratio; IFN, interferon; KPa, kilopascal; MELD, model for end‐stage‐liver disease; PR, peg‐IFN 
plus RBV; RAS, resistant‐associated substitution; RBV, ribavirin; SAE, serious adverse event; SMV, Simeprevir; 
SOF, Sofosbuvir; SVR, sustained virological response; WBD, weight‐based dose  
Key Points 
 The combination of SOF/SMV with or without RBV was highly effective (SVR 92.3%) in real‐life cirrhotic 
patients infected with genotypes 1 or 4. Efficacy was reduced in patients with advanced liver disease and portal 
hypertension. 
 The use of RBV, female gender, MELD<10, Albumin levels≥35 g/L and the lack of exposure to triple therapy 
were independent predictive factors of SVR. 
 Safety was globally good and the rate of severe adverse events and/or premature discontinuations was rare. 
 This antiviral option may still be considered as an alternative for compensated cirrhotic patients. 
 
 
 
 
 
  
1 INTRODUCTION 
Chronic infection with the hepatitis C virus (HCV) constitutes a major global disease.
1,2
 Successful 
antiviral therapy leading to sustained virological response (SVR) significantly reduces the risk of HCV‐
related cirrhosis and its complications
3,4
 and improves patients′ quality of life.5 In Spain, the 
seroprevalence of HCV is around 2%, being genotype (GT)1b the more frequent (>70%).
1 
 
Until 2014, interferon (IFN)‐based therapies were the only option for viral eradication. However, its 
use was contraindicated in decompensated liver disease
6
 and tolerability and efficacy were low in patients 
with cirrhosis. Triple therapy increased SVR rates to 70%‐75% but further worsened safety profile.7 The 
main change in HCV therapy has been the introduction of oral direct acting antivirals (DAA). The first 
IFN‐free DAA combination was the protease‐inhibitor Simeprevir (SMV) plus the polymerase‐inhibitor 
Sofosbuvir (SOF). This combination was first explored in a small phase‐II trial8 including 167 GT1 
patients, 41 of whom were cirrhotics. Treatment was well tolerated and overall SVR rate was 92.2%. 
Based on these excellent results, SOF/SMV was approved by the FDA and EMA for the treatment of 
HCV.
9-11
 At that time, many difficult‐to‐treat patients with advanced liver disease, previous treatment 
failures or IFN contraindications underwent SOF/SMV. Since then, several studies of real‐life have been 
published.
12-16
 One of the largest was the US‐TARGET cohort,12 which included 491 cirrhotic patients 
(45% with prior hepatic decompensation). Most of these patients (79.8%) received SOF/SMV without 
RBV. Noteworthy, SVR rate was significantly lower in cirrhotic patients (80.5%) than in non‐cirrhotic 
patients (89.5%). Similar results were observed in two phase‐III clinical trials evaluating SOF/SMV 
without RBV, in which SVR was achieved in 83% of the cirrhotic patients
17
 compared to 97% in non‐
cirrhotic patients.
18 
 
Despite other antiviral combinations have replaced SOF/SMV in many countries, in consonance with 
the recent international guidelines,
19
 there is still a high need for effective and affordable antiviral options 
in many areas of the world. Current access restrictions to new DAA also reinforce the need for updated 
data and evidence‐based alternatives for HCV patients.  
 
In Spain, the combination of SOF/SMV was extensively used in many referral centres. The existence 
of a national collaborative register allowed us to perform this study, in which we aimed at analysing the 
safety and efficacy of this combination in a large cohort of Spanish patients with well‐defined liver 
cirrhosis, infected with GT1 and 4. 
2 PATIENTS AND METHODS 
2.1 Study 
This was a retrospective, non‐interventional, national, multicentre and collaborative study, evaluating 
the efficacy and safety of SOF/SMV with or without RBV for HCV‐infected patients with cirrhosis in 
routine clinical practice in Spain. Data were collected through a National Registry (HEPA‐C) and through 
a non‐HEPA‐C database from transplant centres. 
2.2 Patients 
The study recorded data of efficacy and safety from all cirrhotic patients infected with HCV GT1 
(1a/1b) or 4, undergoing SOF/SMV with or without RBV between January 2014 and December 2015. 
Demographic, clinical, and virological data at baseline, treatment, and follow‐up were collected. Cirrhosis 
was defined by transient elastography≥14 kPa, liver biopsy, clinical evidence (such as presence of 
gastroesophageal varices or liver decompensation), or at least two ultrasonographical criteria (liver 
surface nodularity, enlarged spleen or portal vein diameter>12 mm). No other inclusion/exclusion criteria 
were applied. Patient follow‐up was planned for 12 weeks after treatment interruption; safety data were 
reported for any patient receiving at least one dose of DAA. As it was a retrospective non‐interventional 
analysis of common clinical practice, no specific informed consent was applied. This study was approved 
by the Research Ethics Committee of Hospital Clinic Barcelona. 
2.3 Treatment 
The duration of therapy (12 or 24 weeks) and the use and starting dose of RBV, was planned at the 
discretion of the treating physician, in accordance with the national and international recommendations at 
that time
20,21
 and the product labels.
22-24
 According to the Guidelines, patients with compensated cirrhosis 
should be treated for 12 weeks with daily weight‐based dose (WBD) of RBV (1000 or 1200 mg in 
patients <75 kg or ≥75 kg, respectively).19,20 Lower doses of RBV were considered by the authors as non‐
WBD. In those patients with contraindications or poor tolerance to RBV, treatment was extended for 
24 weeks without RBV.  
2.4 Efficacy 
Sustained virological response (SVR) was defined as undetectable HCV‐RNA 12 weeks after the end 
of treatment. Virological failure was defined as detectable HCV‐RNA at any time during treatment or 
follow‐up. HCV‐RNA levels were determined using either the COBAS AmpliPrep®/COBAS TaqMan® 
(Roche Molecular Systems, Pleasanton, CA, USA; lower limit of detection [LLOD] 15 IU/mL) or the 
m2000SP/m2000RT (Abbott Molecular, Des Moines, IL, USA; LLOD 12 IU/mL) real‐time PCR‐based 
assays, according to the different centres. Viral load measurements were reported at baseline and at 
12 weeks after treatment completion.  
2.5 Safety 
All the adverse events (AE) reported by the investigators occurring during therapy or follow‐up were 
registered retrospectively. The more usual events related with SOF, SMV or RBV were specified in order 
to simplify and unify the reports. These AE were: anaemia, asthenia, pruritus, hyperbilirubinaemia, 
dermatological events and digestive symptoms (diarrhoea, nausea or abdominal pain). Anaemia was 
defined as “nadir haemoglobin level≤12 g/dL during therapy”; severe anaemia was defined as “nadir 
haemoglobin level≤10 g/dL during therapy”.  
 
Severe adverse events (SAE) were defined as any life‐threatening event (leading to hospital 
admission, prolonged hospital admission or death), or any event that was considered serious based on the 
treating physician′s judgment. Incidence and reason for treatment discontinuation, liver decompensation 
and deaths were also recorded. 
2.6 Statistical analysis 
For descriptive purposes, quantitative variables are presented as mean, range and/or interquartile 
ranges (IQR), as appropriate. Categorical variables are presented as number and percentages. Efficacy 
and safety analyses were performed using the chi‐squared test (categorical dicotomical variables), 
Student′s t test or Mann‐Whitney test for comparisons between independent groups, at a significance level 
of .05. All the variables were tested first in univariate analysis, and included in a multivariate stepwise 
logistic‐regression analysis if significant; selection of independent covariates by the regression model was 
based on a backward elimination procedure, retaining covariates with P<.05. Statistical analysis was 
performed with the SPSS® Statistics package, version 21 (IBM® Corporation, Somers, NY, USA).  
  
3 RESULTS 
3.1 Patient characteristics 
Thirty Spanish centres participated in this study, accounting for 1012 cirrhotic patients infected with 
GT1 or four treated with SOF/SMV±RBV. Out of them, 911 (94.2%) were evaluable for the efficacy 
analysis and 898 (92.8%) reported data for the safety profile (see Figure 1 for detailed flowchart).  
 
 
 
Figure 1. Flowchart of patients. (*) 70 patients had no data for safety purposes; (**) 57 patients had no data for efficacy purposes. 
GT, genotype; SOF, sofosbuvir; SMV, simeprevir 
Regarding baseline features, 60.2% were males, median age was 60% and 69% were infected with 
subgenotype 1b. Importantly, 63% of included individuals were previous non‐responders. One‐third of 
patients had oesophageal varices and/or history of previous decompensation at baseline. The majority of 
patients were planned to receive RBV (61%) and treated for 12 weeks (92.4%). Detailed demographic 
and clinical characteristics are showed in Table 1. 
Table 1. Baseline Demographics of All Patients Who 
Started Treatment With Simeprevir Plus Sofosbuvir With or 
Without Ribavirin (n=968) 
Variables 
Total Cohort 
(n=968) 
  
Gender (M) (n, %) 583 (60.2) 
Age (y) 60 (19‐94) 
Genotype (n, %) 
1a 191 (19.7) 
1b 671 (69.3) 
1 (n/t) 23 (2.4) 
4 82 (8.5) 
NA 1 (0.1) 
Viral Load HCV‐RNA (log10) (UI/mL)  6.08 (1.28‐7.73) 
Previous treatment experience (n, %) 
Yes 609 (62.9) 
No 355 (36.7) 
NA 4 (0.4) 
Previous triple therapy (TT) (protease‐
inhibitor+Peg/RBV) 
119 (12.3) 
Diagnosis of Liver Cirrhosis 
Elastographic criteria 326 (33.7) 
Ultrasound Criteria 60 (6.2) 
Clinical Criteria 179 (18.5) 
More than 1 criteria 383 (39.6) 
Transient Elastography (Kpa)a 
22 (4‐91) [P25‐P75: 
16.8‐33.3]  
TE ≥21 Kpa (n, %) 393 (40.6) 
Child‐Pugh score (n, %) 
 A 738 (76.2) 
B 159 (16.4) 
C 8 (1) 
NA 63 (6.5) 
MELD score (median, range); IQR [P25‐
P75]
b 
8 (7‐26); IQR 
[P25‐P75: 7‐10]  
MELD score ≥10 (n, %) 260 (26.9) 
Any previous Liver Decompensation (n, 
%) 
297 (30.7) 
Ascites 135 (13.9) 
Hepatic encephalopathy 12 (1.2) 
Variceal Bleeding 43 (4.4) 
More than 1 decompensation 75 (7.6) 
Not especified 32 (3.3) 
Oesophageal or gastric varices at 
baseline (n, %)c 
320 (33.1) 
Platelets count (109/L)  98 (12‐647) 
Platelet count ≤100 (n, %) 483 (49.9) 
Haemoglobin (g/dL) 14 (7.3‐19) 
ALT (UI/L) 71 (5‐513) 
Bilirubin (mg/dL) 0.99 (0.20‐6) 
Albumin (g/L) 39 (22‐52) 
Albumin level <35 g/L (n, %) 198 (20.5) 
Table 1. Baseline Demographics of All Patients Who 
Started Treatment With Simeprevir Plus Sofosbuvir With or 
Without Ribavirin (n=968) 
Variables 
Total Cohort 
(n=968) 
Treatment planned duration (n, %) 
12 wk 894 (92.4) 
24 wk 39 (4) 
Other durations 9 (0.9) 
NA 26 (2.7) 
Planned use of RBV (n, %) 
Yes 590 (61) 
No 357 (37) 
NA 20 (2) 
  
 
M, male; F, female; NA, not available; HCV, hepatitis C 
virus; TE, transient elastography; KPa, kilopascals; MELD, 
Model for End‐Stage Liver Disease; IQR, interquartile 
range; RBV, ribavirin; n/t, not typable; Peg, pegylated.  
Quantitative variables are presented as mean and range 
and/or interquartile ranges (IQR, P25‐P75) as appropriate. 
Categorical variables are presented as number and 
percentages (n, %). Data refer to the whole population 
receiving at least one dose of the study medication. For 
efficacy purposes, only 911 patients could be analysed.  
a Available in 705 patients.  
b Available in 857 patients.  
c Available in 737 patients.  
 
 
3.2 Efficacy analysis 
Virological evaluation at follow‐up 12 was available in 911 (94.2%) patients. Overall, the crude SVR 
rate was 92.3%. No significant differences of efficacy were detected between genotypes (92.4% in GT1 
vs 91.1% in GT4, P=.4), subgenotypes (94.3% in GT1a vs 91.7% in GT1b, P=.15) or treatment duration 
(92.3% for 12 weeks vs 96.7% for 24 weeks, P=.32). Similar SVR rates were also obtained in naive and 
previously non‐responders to dual therapy (PR; 94.2% vs 91.2%, P=.07). However, the subgroup of 
patients who had failed to previous triple therapy (n=115) had lower SVR (86.1%; P=.03, compared to 
PR). SVR rates were higher in female patients compared to males (94.4% vs 90.9%, P=.03; Figure 2A).  
 
 
 
Figure 2 (A) SVR12 Rates Among Patients With Available Outcomes according to baseline and treatment characteristics. (^) 
Refers to GT1 vs GT4 y GT1a vs GT1b (P=ns). (B) SVR12 Rates Among Patients With Available Outcomes according to liver 
disease severity. W/RBV, with Ribavirin; wo/RBV, without Ribavirin; GT, genotype; wk, weeks; TE, treatment experienced; TT, 
triple therapy with a protease‐inhibitor; CPA, Child‐Pugh A score; CPB/C, Child‐Pugh B/C; MELD, model for end‐stage liver 
disease; plats, platelets; Alb, albumin; TE, transient elastography; Kpa, kilopascals  
 
  
Patients with more advanced liver disease (Child‐Pugh score B/C, MELD score≥10, or indirect 
markers of portal hypertension such as platelets≤100000 or transient elastography≥21Kpa)25 presented 
significantly lower SVR rates (84.4%‐91.9%) when compared to patients with less advanced liver disease 
(Child‐Pugh A, MELD score<10, no markers of portal hypertension; 93.8%‐95.9%; P<.05; Figure 2B).  
 
The majority of patients (62.8%) received concomitant RBV as part of their treatment, independently 
of the gender (P=.14). In most of them (59.7%), RBV was dosed according to weight. Overall, the use of 
RBV was associated with significantly higher SVR rates: 93.9% vs 89.7% in those without RBV (P=.02). 
However, we found no differences neither between patients receiving weight‐based dose (WBD) vs non‐
WBD of RBV (93.4% vs 94%, P=.47), nor between the different subgenotypes (depicted in Figure 3). 
RBV was similarly used irrespectively of the severity of cirrhosis (66.3% in Child A vs 63.7% in Child 
B/C, P=ns). Noteworthy, in patients with advanced liver disease (Child‐Pugh B/C, n=157) treated without 
RBV, SVR decreased to 82.5% (vs 88% if RBV was added), although this difference did not reach 
statistical significance (P=.23).  
 
 
 
Figure 3 SVR12 Rates according to the use of RBV in the different viral subgenotypes. (*) Subgenotype was not available in 21 
GT1 patients which were not included in the bars 
In the multivariate analysis, the use of RBV (HR 1.93 [1.13‐3.28], P=.015) and female gender (HR 
2.15 [1.19‐3.89], P=.011) were independent predictors of SVR, whereas a MELD score≥10 (HR 0.51 
[0.28‐0.91], P=.024), baseline albumin levels<35 g/L (HR 0.43 [0.23‐0.78], P=.006) and previous failure 
to triple therapy (HR 0.33 [0.17‐0.64], P=.001), were inversely associated with the achievement of SVR 
(Table 2). 
 
 
 
 
  
Table 2. Univariate and multivariate predictors of SVR in the efficacy cohort (n=911) 
Variables 
SVR 
(n=841) 
Non SVR 
(n=70) 
Pa (Univariate 
analysis)  
HR (95% CI) 
Univariate 
Pb (Multivariate 
analysis)  
HR (95% CI) 
Multivariate 
       
Age (y) 60 (53‐68) 58.9 (51‐66) .24 1.01 (0.99‐1.04) 
  
Gender (F) (vs M) 
339/839 
(40.4%) 
20/70 
(28.6%) 
.05  1.69 (0.99‐2.89) .011  2.15 (1.19‐3.89) 
Use of RBV (n, %) 
563/822 
(65.2%) 
35/69 
(50.7%) 
.02  1.76 (1.08‐2.88) .015  1.93 (1.13‐3.28) 
GT1b (vs GT1a) 
592/761 
(77.8%) 
53/63 (84%) .24 0.66 (0.32‐1.32) 
  
Child‐Pugh score B/C 
(vs CPA) 
135/788 
(17.1%) 
22/65 
(33.8%) 
.001  0.40 (0.23‐0‐69) 
  
MELD≥10 (n, %)c 
214/742 
(28.8%) 
32/65 
(49.2%) 
.001  0.42 (0.25‐0.69) .024  0.51 (0.28‐0.91) 
Transient elastography 
(KPa) 
21.8 (16.6‐
32.8) 
26.8 (19.6‐
35.4) 
.16 0.98 (0.96‐1.00) 
  
Baseline Oesophageal 
varices 
280/644 
(43.5%) 
25/55 
(45.5%) 
.77 0.92 (0.53‐1.60) 
  
Platelets (109/mL)  
100 (68‐
141) 
82 (59‐113) .04  1.01 (1.00‐1.01) 
  
Platelet count ≤100 
(109/mL)  
415/817 
(50.8%) 
48/69 
(69.6%) 
.003  0.45 (0.26‐0.76) 
  
Albumin (g/L) 
39.9 (35.9‐
42.3) 
37 (32‐40.7) <.001  1.09 (1.04‐1.14) 
  
Albumin levels <35 
(g/L) 
157/800 
(19.6%) 
29/69 (42%) <.001  0.34 (0.20‐0.56) .006  0.43 (0.23‐0.78) 
Previous failure to TT 
(n, %) 
99/841 
(11.8%) 
16/70 
(22.9%) 
.009  0.45 (0.24‐0.81) .001  0.33 (0.17‐0.64) 
       
 
M, male; GT, genotype; MELD, model for end‐stage liver disease; KPa, kilopascals; SVR, sustained virological response; OR, odds 
ratio; CI, confidence interval.  
Statistically significant values are represented in bold numbers.  
a Univariate analysis (as appropriate): T Student/U Mann Whitney for continuous variables; Chi square in categorical variables.  
b Multivariate analysis: logistic regression stepwise.  
c MELD score also remained in the uni and multivariate analysis when considered as a continuous variable.  
3.3 Safety analysis 
Safety and tolerability was available in 898 patients (92.8%). Overall, safety was good despite the 
high incidence of adverse events (AE; 48.6%; Table 3). Noteworthy, most of the AE were mild (91%) 
and mainly occurred in patients receiving RBV (72.4%; P<.01). Some AE (2.8%), were reported as not 
related with antiviral treatment.  
  
Table 3. Safety profile 
Safety Events Cohort (n=898) 
  
Any Adverse Events (AE) (n, %) 436 (48.6%) 
Treatment related AE 411 (45.8%) 
Non‐treatment‐related AE 25 (2.8%) 
Unknown association 28 (3.1%) 
AE according to treatment arm (n, %) 
RBV‐cohort (n=527) 312 (72.4%) 
Non RBV‐cohort (n=323) 119 (27.6%) 
More frequent AE (global incidence ≥10%)a 
Anaemia (nadir Hb≤12 g/dL) 403 (44.9%) 
Asthenia 294 (32.8%) 
Dermathologic events 136 (15.2%) 
Hyperbilirrubinaemia 308 (34.3%) 
Anaemia according to treatment arm (n, %) 
RBV‐group  
Anaemia (nadir Hb≤12 g/dL) 294 (54%) 
Severe anaemia (Hb≤10 g/dL) 73 (13.4%) 
Nadir level of Hb (g/dL) 11.9 (6.3‐17.5) 
Non RBV‐group  
Anaemia (nadir Hb≤12 g/dL) 105 (32.9%) 
Severe anaemia (Hb≤10 g/dL) (n, %) 42 (13.2%) 
Nadir level of Hb (g/dL) 13.2 (6.5‐18.4) 
Management of anaemia 
RBV dose reduction/discontinuation 109 (35.4%)/16 (5.2%) 
Use of EPO/Blood transfusion 15 (4%)/21 (5.2%) 
Serious Adverse Events (SAE)b (n, %)  53 (5.9%) 
Early discontinuation because of AEc (n, %)  23 (2.6%) 
Liver decompensationd 56 (6.2%) 
Deathse 31 (3.5%) 
Liver‐related causes 18 (58.1%) 
Non‐liver‐related causes 9 (29%) 
Unknown 4 (12.9%) 
  
 
a Other AE with an incidence <10%: insomnia (7.6%), headache (6.7%), digestive events (6.1%), flu‐syndrome (1.9%), renal 
impairment (1.6%), infections (5.4%).  
b Serious Adverse events: severe allergic reaction (n=1), suicide (n=1), de novo HCC (n=2), pneumonia (n=1), unknown cause of 
intratreatment non‐hepatic exitus (n=2), neurologic disorder (n=1), medular aplasia (n=1), de novo liver decompensation (n=24), 
liver function impairment (n=2), myositis (n=1), unknown (n=17).  
c Early discontinuation: severe allergic reaction (n=1), aplasia medular (n=1), on‐treatment virological failure (n=1), de novo HCC 
(n=1), neurologic disorder (n=1), liver decompensation (n=6), liver function impairment (n=4), suicide (n=1), unknown cause of 
intratreatment non‐hepatic exitus (n=2), tiredness (n=1), pneumonia (n=1), pruritus/rash (n=2), liver transplantation (n=1).  
d Includes de novo decompensation and impairment of a previous stable situation.  
e Deaths: pneumonia leading to sepsis (n=1), suicide (n=1), lymphoma (n=1), liver disease progression (n=12), HCC progression 
(n=5), unknown (n=11).  
 
 
  
In the overall population, the most common AE (≥10%) were: anaemia (44.9%), asthenia (32.7%), 
hyperbilirrubinaemia (34.3%) and dermatological events (15.2%). As expected, anaemia (nadir 
haemoglobin≤12 g/dL) was significantly more frequent in patients receiving RBV (54% vs 32.9% in 
those without RBV, P<.01). Severe anaemia (nadir haemoglobin≤10 g/dL) was reported in 115 patients 
(12.8%); 63.5% of them received RBV. Anaemia was mainly managed by RBV dose reduction (35.4%) 
or discontinuation (5.2%). Importantly, the need for erythropoietin or blood transfusion was very 
uncommon (4% and 5.2% respectively).  
 
Severe adverse events (SAE) were registered in 53 patients (5.9%). Early treatment discontinuation of 
antiviral therapy occurred in a minority of cases (n=23, 2.6%). Decompensation of liver cirrhosis was 
reported in 56 patients (6.2%) and included both de novo events (n=23), as well as worsening of a 
previous stable condition (n=33). Thirty‐one patients died (3.5%) during the period of the study, mainly 
(58%) because of liver‐related causes. Details of SAE are depicted in Table 3.  
 
Hepatocellular carcinoma (HCC) recurrence was reported in nine of 33 (27.3%) patients with 
documented HCC at the time of treatment initiation. Moreover, 18 (1.9%) patients were diagnosed with 
HCC during the study period. HCC progression was the cause of death in five cases. However, this study 
was not conducted to assess recurrence or incidence of HCC, and these data must be considered with 
caution. 
4 DISCUSSION 
Real‐world clinical experience is relevant to validate efficacy and safety of drugs after controlled 
clinical trials and approval by Health Authorities. Indeed, efficacy in real‐life is often worse than 
reported, as patients are more heterogeneous, physicians may face unusual circumstances, and some 
unexpected safety concerns may also be raised when treating complex patients. 
 
Based on the favourable results of SOF/SMV in clinical trials,
17,18
 many real‐life cohort studies were 
published after drug approval in 2014.
12,15,16,26
 Safety profile was good
27
 whereas efficacy was reported to 
be excellent in non‐cirrhotics (SVR 92%‐94%) but slightly lower in patients with cirrhosis (SVR 82%‐
85%).
12,28
 For this reason, we aimed at assessing the efficacy and safety of SOF/SMV in our cohort of 
Spanish cirrhotic patients. This is, at the best of our knowledge, the largest cohort of cirrhotic patients 
treated with this combination.  
 
SOF/SMV treatment with or without RBV achieved overall SVR rates of 92.3% in our cohort, which 
is largely enriched by patients with advanced liver disease and other unfavourable predictors of antiviral 
response: up to one‐third had a history of previous liver decompensation and/or oesophageal varices at 
baseline, and the proportion of patients with previous treatment failure to PR or triple therapy was 
remarkable. This may also explain the frequent use of RBV, which was indicated in two‐thirds of 
patients. As expected, SVR rates were slightly lower in patients with more advanced liver disease (Child‐
Pugh B/C: SVR 86%; MELD≥10: SVR 87%; Albumin levels<35 g/L: SVR 84.4%) and in patients who 
had failed to triple therapy (SVR 86.1%). At multivariate analysis, the use of RBV, female gender, 
MELD score<10, baseline albumin levels≥35 g/L and no previous exposure to triple therapy were 
identified as independent predictors for SVR. 
 
It is important to notice that the overall efficacy of this regimen in our cohort is clearly higher than the 
efficacy published in other large series.
28
 There are several potential explanations for these results. Firstly, 
a more frequent use of RBV (with potential additive antiviral effect), which might be important in 
difficult‐to‐treat patients. Noteworthy, this beneficial effect was independent of the starting dose of RBV. 
As stated above, RBV was used in almost 63% of patients, compared to only 22% in the TARGET 
cohort,
12
 where RBV was not associated with improved SVR rates. Conversely, the STIly Italian 
multicentric study
29
 reported high SVR rates in a cohort of 263 cirrhotic patients treated with SOF/SMV 
(82% with RBV). Although no differences in efficacy were described between those receiving RBV or 
not (91% vs 96%), patients treated with RBV presented a more advanced liver disease, probably 
impacting global results. Another multicentric study including 270 GT1 compensated cirrhotics treated 
for 12 weeks with SOF/SMV plus RBV
30
 reported excellent efficacy (SVR 95.9%) and tolerability (<2% 
SAE,<6% discontinuation). On the other hand, supporting the usefulness of RBV in cirrhotic patients, the 
OPTIMIST 2 phase‐III trial17 reported efficacy rates of only 83% in a cohort of 103 compensated 
cirrhotic patients treated for 12 weeks with SOF/SMV without RBV. A second explanation for the good 
results obtained in our cohort is the lower prevalence of GT1a‐infected patients in Spain, and the reduced 
European prevalence of Q80K mutation in GT1a compared to USA.
31,32
 Although the negative impact of 
Q80K resistant‐associated substitution (RAS) in GT1a patients undergoing SOF/SMV is not as evident as 
in those treated with PR plus SMV,
33,34
 SVR rates were lower in patients harbouring this RAS both in the 
COSMOS
8
 and OPTIMIST‐II30 trials. This is in line with the reduced SVR rates observed in patients 
previously exposed to a protease‐inhibitor as part of triple therapy. We did not find a difference in 
efficacy between GT1a and GT1b patients, but this may be explained by the wide use of RBV. A third 
issue regarding the high efficacy of SOF/SMV in our population is the fact that patients were treated by 
hepatologists in referral centres rather than in community‐based practice; this may result in greater 
treatment adherence, better management of AE and, secondarily, in higher response rates.
35
 
 
Safety was good in our cohort of cirrhotic patients. As expected, AE were more frequent in patients 
receiving RBV. However and similarly to previous reported data, only a few proportion of patients 
presented SAE or required premature treatment interruption. Anaemia was easily managed mainly by 
dose reductions of RBV. Considering the warning FDA/EMA reports regarding the use of protease‐
inhibitors in advanced cirrhosis, treating physicians were prone to assess the liver‐related SAE. In our 
experience, SAE were rare (5.9%) and decompensation rates low (6.2%). The data can be considered 
within the expected range of events in patients not undergoing therapy, although a control group would be 
necessary to support this statement. Nevertheless, our study reinforces that the use of SOF/SMV in 
compensated cirrhosis is safe. 
 
This study has the inherent limitations related to its observational, multicentric and real‐world design. 
This is more evident for the safety evaluation, since data were not captured prospectively and might be 
incomplete. A potential bias for using RBV by the treating physicians cannot be excluded. Nevertheless, 
this large real‐life experience gives an important insight into the effectiveness and safety of SOF/SMV for 
GT1 and GT4 cirrhotic patients. 
 
The American Association Guidelines for treatment of HCV
36
 consider SOF/SMV as an option for 
non‐cirrhotic GT1 patients; however, SOF/SMV remains as a secondary alternative in those with 
compensated cirrhosis and should be administered for 24 weeks. In the European Guidelines in 2016,
19
 
SOF/SMV is not considered an optimal alternative for GT1 patients anymore. In both cases, the decision 
is supported by the slightly better results of other DAA (Sofosbuvir/ledipasvir, Sofosbuvir/Velpatasvir, 
Paritaprevir/Ombitasvir/ritonavir with Dasabuvir, or Grazoprevir/Elbasvir) that emerged afterwards in 
2015‐2016 improving antiviral efficacy and minimizing the need for RBV.19,36 However, based on our 
results, SOF/SMV (with RBV addition) should be still considered an effective and safe therapy for GT1 
and GT4 cirrhotic patients, if other combinations are not available or affordable. This is the case for many 
countries in Central and South America, as well as other regions of the world such as Africa and Asia.  
 
Moreover, the use of SMV in such a large cohort of cirrhotic patients is important to reinforce the 
safety profile of protease‐inhibitors in this setting, where other agents from this class (voxilaprevir, 
glecaprevir) will be widely used in the near future. 
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